American Association of Cancer Research (AACR) Annual Meeting
Phase I/II Study of Dianhydrogalactitol in Patients with Recurrent Malignant Glioblastoma
Phase I/II Study of Dianhydrogalactitol in Patients with Recurrent Malignant Glioblastoma
Enhanced in vitro activity of dianhydrogalactitol (VAL-083) in combination with platinum drugs: impact of p53 and platinum-resistance
Phase I/II Study of Dianhydrogalactitol in Patients with Recurrent Malignant Glioma
The unique mechanism of action of dianhydrogalactitol (VAL-083) may provide a new treatment option for chemo-resistant cancers
Dianhydrogalactitol (VAL-083) Offers Potential Therapeutic Alternatives in the Treatment of Pediatric Brain
Exploring the Molecular Mechanisms of Dianhydrogalactitol (VAL-083) in Cancer Treatment
Dianhydrogalactitol (VAL-083) enhances activity of platinum drugs in non-small cell lung cancer
A comparison of mechanisms and cytotoxic activity of dianhydrogalactitol (VAL-083) to cisplatin in ovarian tumor models harbouring wild-type and mutant p53
Tuesday, September 8, 2015 poster session. Post-Market Clinical Trial of Dianhydrogalactitol in the Treatment of Relapsed or Refractory Non-Small Cell Lung Cancer
Tuesday, September 8, 2015 poster session. Update on Phase 1/2 study of VAL-083 (dianhydrogalactitol) in patients with recurrent malignant glioma